Charles River Laboratories International Inc. Stock Slides 3.0%, Underperforms Market
The Three-year Earnings Decline Is Not Helping Charles River Laboratories International's (NYSE:CRL Share Price, as Stock Falls Another 9.9% in Past Week
The FDA Is 'Finished' as Firings Sweep Health Agencies. Drug Stocks Are Falling. -- Barrons.com
The "Liberation Day" of Trump's tariffs is approaching, and the pharmaceutical Industry may not be among the targets.
According to reports, President Trump of the USA is expected to announce a series of broader tariff measures on local time April 2 (Wednesday), which will not include any specific details on Pharmaceutical tariffs.
Flagship Pioneering Announces Agreement Between Pioneering Medicines and Pfizer to Discover Potential Novel, Selective Inhibitors for Autoimmune Disease
Baird Adjusts Charles River Laboratories International Price Target to $155 From $173, Maintains Neutral Rating
Under Trump's tariff threats, a new "landscape" in the USA: stockpiling medicine!
According to several Company Executives in the Pharmaceutical industry and Logistics companies, due to concerns that the reciprocal tariffs announced by President Trump on April 2 may involve Pharmaceutical products from Europe, some Pharmaceutical companies are taking unusual measures to transport more drugs to the USA via Air Transportation; Two Pharmaceutical companies headquartered in Europe stated to the media this week that they have transported as many Pharmaceutical products to the USA as possible in recent weeks, and they have also learned that other Pharmaceutical companies are taking similar actions.
Charles River Associates (CRA) Announces Vice President Promotions
Hospital Stocks Are Ready to Rebound, Deutsche Bank Says
Charles River, Valo Health Identify First Lupus Treatment Candidate Using Logica AI Platform
Proposed Medicaid Cuts Would Devastate Local Economies: Report -- Barrons.com
Why Charles River Laboratories International, Inc. (CRL) Is Among the Best Diagnostics Stocks to Invest in Right Now
Goldman Sachs Downgrades Charles River(CRL.US) to Hold Rating, Cuts Target Price to $170
Demystifying Charles River: Insights From 10 Analyst Reviews
Charles River (CRL) Up 1.9% Since Last Earnings Report: Can It Continue?
Icon, Charles River Downgraded as Goldman Sachs Reviews CRO Space
Charles River Associates Management to Meet With Barrington
This FedEx Analyst Turns Bearish; Here Are Top 5 Downgrades For Friday
Express News | Goldman Sachs Downgrades Charles River to Neutral, Lowers Price Target to $170
Charles River Analyst Ratings